For NSCLC, alternative immune checkpoints, such as B7x and HHLA2, were found to be expressed in the majority of PD-L1-negative cases, which inhibited T cell receptor (TCR)-mediated CD4+, CD8+ T cell proliferation, and T cell cytokine production [38]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.